Abstract
Background/Aim
Overexpression of metastatic tumor antigen-1 (MTA-1) is suggested to be associated with frequent postoperative recurrence and poor survival of hepatocellular carcinoma (HCC) patients. In this study, we intended to determine clinical factors predisposing the overexpression of MTA-1 in patients with hepatitis B virus (HBV)-associated HCC and also examine whether MTA-1 overexpression affects the survival periods of these patients treated with curative surgical resection.
Methods
A total of 303 patients with HBV-associated HCC who underwent curative surgical resection were subjected. The expressions of MTA-1 in HCC and surrounding non-tumor liver tissues were evaluated using the immunohistochemical method. The clinical, radiological and histological characteristics of the patients were analyzed in relation to the expression of MTA-1 to find predisposing factors of MTA-1 overexpression.
Results
MTA-1 was overexpressed in 104 HCC tissues (34.3 %) and none of the surrounding non-tumor tissues. Clinically, MTA-1 overexpression was significantly associated with younger age, female gender, higher serum alpha-fetoprotein level, and Child–Turcotte–Pugh class A. Also, portal vein thrombosis, microvascular invasion, capsular invasion and poorly histological differentiation were associated with overexpression of MTA-1. The cumulative survival rates were significantly lower in patients with MTA-1 overexpression compared with those in the MTA-1 negative group (P = 0.03). In addition to the overexpression of MTA-1, the presence of microvascular or capsular invasion was a significant factor determining the poor survival of the patients with HBV-associated HCC after curative resection.
Conclusions
MTA-1 is overexpressed in patients with HBV-associated HCC of invasive nature. MTA-1 overexpression is associated with shorter survival periods of patients with HBV-associated HCC after curative resection.
Similar content being viewed by others
Abbreviations
- AFP:
-
Alpha-fetoprotein
- CTP:
-
Child-Turcotte-Pugh
- CT:
-
Computed tomography
- E–S:
-
Edmondson–Steiner
- HBV:
-
Hepatitis B virus
- HCC:
-
Hepatocellular carcinoma
- HCV:
-
Hepatitis C virus
- HIF:
-
Hypoxia inducible factor
- HR:
-
Hazard ratio
- MTA-1:
-
Metastatic tumor antigen-1
- NuRD:
-
Nucleosome remodeling and histone deacetylation
- PVT:
-
Portal vein thrombosis
References
Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–543.
El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27–S34.
Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan. Lancet. 1981;2:1129–1133.
Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol. 2002;8:193–199.
Qu LS, Jin F, Huang XW, et al. High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. J Gastrointest Surg. 2010;14:1111–1120.
Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001;234:63–70.
Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434–1440.
Kokudo N, Ishizawa T, Hasegawa K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134:1908–1916.
Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–524.
Ryu SH, Chung YH, Lee H, et al. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology. 2008;47:929–936.
Kumar R, Wang RA, Bagheri-Yarmand R. Emerging roles of mta family members in human cancers. Semin Oncol. 2003;30:30–37.
Sasaki H, Moriyama S, Nakashima Y, et al. Expression of the MTA-1 mRNA in advanced lung cancer. Lung Cancer. 2002;35:149–154.
Hofer MD, Kuefer R, Varambally S, et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res. 2004;64:825–829.
Hofer MD, Tapia C, Browne TJ, et al. Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue. Arch Pathol Lab Med. 2006;130:989–996.
Toh Y, Oki E, Oda S, et al. Overexpression of the MTA-1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int J Cancer. 1997;74:459–463.
Moon HE, Cheon H, Chun KH, et al. Metastasis-associated protein 1 enhances angiogenesis by stabilization of HIF-1 alpha. Oncol Rep. 2006;16:929–935.
Chan DA, Sutphin PD, Yen SE, et al. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol. 2005;25:6415–6426.
Moon WS, Chang K, Tarnawski AS. Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: relationship to vascular invasion and estrogen receptor-alpha. Hum Pathol. 2004;35:424–429.
Semenza GL, Nejfelt MK, Chi SM, et al. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA. 1991;88:5680–5684.
Yoo YG, Kong G, Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J. 2006;25:1231–1241.
Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996;111:1018–1022.
Di Lelio A, Cestari C, Lomazzi A, et al. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology. 1989;172:389–392.
Katyal S, Oliver JH III, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216:698–703.
Yuki K, Hirohashi S, Sakamoto M, et al. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer. 1990;66:2174–2179.
El-Assal ON, Yamanoi A, Soda Y, et al. Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma. Surgery. 1997;122:571–577.
Kim JH, Choi MS, Lee H, et al. Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. J Gastroenterol Hepatol. 2006;21:588–594.
Chedid A, Ryan LM, Dayal Y, et al. Morphology and other prognostic factors of hepatocellular carcinoma. Arch Pathol Lab Med. 1999;123:524–528.
Chen CH, Chang TT, Cheng KS, et al. Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver Int. 2006;26:766–773.
Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. Hepatology. 2000;32:233–238.
Farinati F, Sergio A, Giacomin A, et al. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Eur J Gastroenterol Hepatol. 2009;21:1212–1218.
Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16:453–463.
Tralhao JG, Kayal S, Dagher I, et al. Resection of hepatocellular carcinoma: the effect of surgical margin and blood transfusion on long-term survival. Analysis of 209 consecutive patients. Hepatogastroenterology. 2007;54:1200–1206.
Kubo S, Tanaka H, Shuto T, et al. Clinicopathologic features and outcome after liver resection for hepatocellular carcinoma in patients with concurrent versus previous chronic hepatitis B. Surg Today. 2005;35:216–222.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jin, YJ., Chung, YH., Kim, J.A. et al. Factors Predisposing Metastatic Tumor Antigen 1 Overexpression in Hepatitis B Virus Associated Hepatocellular Carcinoma. Dig Dis Sci 57, 2917–2923 (2012). https://doi.org/10.1007/s10620-012-2296-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-012-2296-z